{"organizations": [], "uuid": "f9008bb093405e78128b90ebfea8f8be757aa0ed", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-nucana-announces-promising-clinica/brief-nucana-announces-promising-clinical-data-on-nuc-1031-as-front-line-treatment-of-advanced-biliary-tract-cancer-idUSFWN1PE14W", "country": "US", "domain_rank": 408, "title": "BRIEF-Nucana Announces Promising Clinical Data On Nuc-1031 As Front-Line Treatment Of Advanced Biliary Tract Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-19T19:43:00.000+02:00", "replies_count": 0, "uuid": "f9008bb093405e78128b90ebfea8f8be757aa0ed"}, "author": "", "url": "https://www.reuters.com/article/brief-nucana-announces-promising-clinica/brief-nucana-announces-promising-clinical-data-on-nuc-1031-as-front-line-treatment-of-advanced-biliary-tract-cancer-idUSFWN1PE14W", "ord_in_thread": 0, "title": "BRIEF-Nucana Announces Promising Clinical Data On Nuc-1031 As Front-Line Treatment Of Advanced Biliary Tract Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "asco", "sentiment": "none"}, {"name": "nucana plc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 19 (Reuters) - Nucana Plc:\n* NUCANA ANNOUNCES PROMISING CLINICAL DATA AT ASCO GI ON NUC-1031 (ACELARINÂ®) AS FRONT-LINE TREATMENT OF ADVANCED BILIARY TRACT CANCER\n* NUCANA SAYS COMBINATION OF ACELARIN AND CISPLATIN WAS WELL-TOLERATED WITH NO UNEXPECTED ADVERSE EVENTS AND NO DOSE-LIMITING TOXICITIES\n* NUCANA PLC - IN TRIAL, 2 OF 8 PATIENTS RECEIVED ONLY ONE CYCLE OR LESS OF THERAPY DUE TO COMPLICATIONS UNRELATED TO EITHER ACELARIN OR CISPLATIN\n* NUCANA SAYS PLAN TO INITIATE PIVOTAL STUDY OF ACELARIN AND CISPLATIN IN FRONT-LINE ADVANCED BILIARY TRACT CANCER IN 2018\n* NUCANA PLC - ANALYSIS OF PHASE 1B STUDY SHOWED ACELARIN, WHEN COMBINED WITH CISPLATIN WAS WELL-TOLERATED IN FRONT-LINE ADVANCED BILIARY TRACT CANCER\n* NUCANA-STUDY SHOWED ACELARIN, WHEN COMBINED WITH CISPLATIN, ACHIEVED HIGH RESPONSE RATES, WAS WELL-TOLERATED IN FRONT-LINE ADVANCED BILIARY TRACT CANCER Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-01-19T19:43:00.000+02:00", "crawled": "2018-01-19T20:09:59.050+02:00", "highlightTitle": ""}